Soluna Holdings Financial Results
Insight Molecular Diagnostics (iMDx) reported Q3 2026 revenue of $559,000 and provided an update on its FDA de novo submission for GraftAssureDx. The company initiated patient enrollment in its GALACTIC registry study at UCLA Medical Center and appointed a new sales leader to prepare for a potential commercial launch.
- Term
- Q3 2026